Source: ctgov · National Cancer Institute (NCI) · RECRUITING · 2026-05-13
URL: https://clinicaltrials.gov/study/NCT06022822
AI rationale (4/5, tier: emerging): Phase II RCT of urolithin A (explicit PRIORITISE item) measuring mitophagy-linked oxidative stress endpoint in human tissue.
This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men will be accrued and randomized 1:1 to receive a 1000 mg daily dose of Uro-A in two 250 mg capsules PO BID or two placebo capsules BID daily for 3 to 6 weeks prior to RP. The primary endpoint is to determine the effect of Uro-A on decreasing prostate tumor tissue oxidative stress (measured by 8-OHdG) compared to placebo.